Cingulate Inc (CING)

$4.04 -0.02 (-0.49%)
Market Cap 27.43M
Revenue (ttm) 0.00
Net Income (ttm) -15.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 56,500
Avg Vol 170,170
Day's Range N/A - N/A
Shares Out 6.76M
Stochastic %K 34%
Beta -0.74
Analysts Strong Sell
Price Target $27.40

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
sam9420
sam9420 Dec. 25 at 7:31 PM
$CING there are here new persons want to make you afraid and sell your shares cheap to buy them . Be confident about what you own ,be patient and you will win finally.
0 · Reply
SubmarineStox
SubmarineStox Dec. 25 at 8:55 AM
$CING Market tolerance narrows as uncertainty lingers, where each milestone now functions as a credibility checkpoint. The upside case requires evidence, not projection.
0 · Reply
sam9420
sam9420 Dec. 24 at 9:43 PM
$CING They don't need money for May 2026 . They have enough to pdufa date. Patent news or partnership or big investment any time from now. We will see 4.50 by Friday and next week to 4.70$
0 · Reply
iholdTNXPbutIhateSeth
iholdTNXPbutIhateSeth Dec. 24 at 3:46 PM
after $OTLK move over to $CING and $RCKT mone
1 · Reply
SubversionStox
SubversionStox Dec. 24 at 12:24 PM
$CING Market attention is shifting toward whether strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.
1 · Reply
sam9420
sam9420 Dec. 24 at 12:38 AM
$CING next month they will announce about the trade name of CTx-1301 🔥
0 · Reply
Slyfox24
Slyfox24 Dec. 23 at 8:15 PM
$CING This is a rare sub $5 biotech with a legit PDUFA locked in. The FDA put May 31, 2026 for CTX-1301. Which is backed by great phase 3 data showing fast onset and full day adhd control. OMER just landed that huge Novo deal without serious dilution and CING could easily pull off something similar. Big Pharma craves fresh adhd plays in this lucrative market. A buyout/ partnership feels way more likely than them grinding out solo commercialization. The recent 6 million note buys the runway at least into June/July so dilution fears are overblown for now. Analysts are saying strong buy with targets at $58 and up. Now is where real accumulation below $5 is going to happen before the real momentum hits. Bullish
0 · Reply
mmtiddy
mmtiddy Dec. 23 at 8:03 PM
$CING okay did some more research on this, projected revenue for this isnt looking too good either it really seems like just a pdufa play, to me anything above $10 million market cap is too expensive for their adhd drug unless they have something else in pipeline that is in phase 1/2 their drug for pdufa seems pretty meh in an already saturated market + cash on hand is really low, it seems like a pass for me, i might revisit after the offering to sell on news, but rn seems to overvalued
0 · Reply
mmtiddy
mmtiddy Dec. 23 at 7:45 PM
$CING it is rare, $OMER is the only stock I can think of that got that, from funding at this late of a stage, not many companies can get those rewards, there is a lot of risk to me, because they can easily dilute for commercialization reasons, which they would do very soon as well i hope they find funding, think this is one of the only stocks below $5 that has pdufa, which a lot people would accumulate, but if they announce an offering they would leave immediately
0 · Reply
Jumpingfox
Jumpingfox Dec. 23 at 5:30 PM
$CING I’m guessing their will be a dilution unless they can secure financing before the PDUFA. Even with dilution, the outstanding shares should be around $10 million with a $500 Million market cap. Any nay sayers?
1 · Reply
Latest News on CING
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 5 weeks ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 2 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 3 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 4 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 4 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 4 months ago

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 5 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 6 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 8 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 9 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 9 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

sam9420
sam9420 Dec. 25 at 7:31 PM
$CING there are here new persons want to make you afraid and sell your shares cheap to buy them . Be confident about what you own ,be patient and you will win finally.
0 · Reply
SubmarineStox
SubmarineStox Dec. 25 at 8:55 AM
$CING Market tolerance narrows as uncertainty lingers, where each milestone now functions as a credibility checkpoint. The upside case requires evidence, not projection.
0 · Reply
sam9420
sam9420 Dec. 24 at 9:43 PM
$CING They don't need money for May 2026 . They have enough to pdufa date. Patent news or partnership or big investment any time from now. We will see 4.50 by Friday and next week to 4.70$
0 · Reply
iholdTNXPbutIhateSeth
iholdTNXPbutIhateSeth Dec. 24 at 3:46 PM
after $OTLK move over to $CING and $RCKT mone
1 · Reply
SubversionStox
SubversionStox Dec. 24 at 12:24 PM
$CING Market attention is shifting toward whether strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.
1 · Reply
sam9420
sam9420 Dec. 24 at 12:38 AM
$CING next month they will announce about the trade name of CTx-1301 🔥
0 · Reply
Slyfox24
Slyfox24 Dec. 23 at 8:15 PM
$CING This is a rare sub $5 biotech with a legit PDUFA locked in. The FDA put May 31, 2026 for CTX-1301. Which is backed by great phase 3 data showing fast onset and full day adhd control. OMER just landed that huge Novo deal without serious dilution and CING could easily pull off something similar. Big Pharma craves fresh adhd plays in this lucrative market. A buyout/ partnership feels way more likely than them grinding out solo commercialization. The recent 6 million note buys the runway at least into June/July so dilution fears are overblown for now. Analysts are saying strong buy with targets at $58 and up. Now is where real accumulation below $5 is going to happen before the real momentum hits. Bullish
0 · Reply
mmtiddy
mmtiddy Dec. 23 at 8:03 PM
$CING okay did some more research on this, projected revenue for this isnt looking too good either it really seems like just a pdufa play, to me anything above $10 million market cap is too expensive for their adhd drug unless they have something else in pipeline that is in phase 1/2 their drug for pdufa seems pretty meh in an already saturated market + cash on hand is really low, it seems like a pass for me, i might revisit after the offering to sell on news, but rn seems to overvalued
0 · Reply
mmtiddy
mmtiddy Dec. 23 at 7:45 PM
$CING it is rare, $OMER is the only stock I can think of that got that, from funding at this late of a stage, not many companies can get those rewards, there is a lot of risk to me, because they can easily dilute for commercialization reasons, which they would do very soon as well i hope they find funding, think this is one of the only stocks below $5 that has pdufa, which a lot people would accumulate, but if they announce an offering they would leave immediately
0 · Reply
Jumpingfox
Jumpingfox Dec. 23 at 5:30 PM
$CING I’m guessing their will be a dilution unless they can secure financing before the PDUFA. Even with dilution, the outstanding shares should be around $10 million with a $500 Million market cap. Any nay sayers?
1 · Reply
mmtiddy
mmtiddy Dec. 23 at 1:38 PM
$CING I want to buy, but their cash position seems a bit worry, any advice?
4 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 9:35 PM
$CING RELAYING DATA TO 1.80* KEY !
1 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 9:34 PM
$CING NEED U FOR MY TELEPORT HALT STOCK CUT N PASTE SOME OF YOR OLD MOVEMENT
2 · Reply
jAug94
jAug94 Dec. 22 at 8:27 PM
$CING keep buying more
0 · Reply
sam9420
sam9420 Dec. 22 at 12:54 AM
$CING we will see 4.30 today
2 · Reply
wanderlust222
wanderlust222 Dec. 20 at 2:41 AM
$CING 3k shares here reporting for duty 🫡 Hopefully this thing takes hold and gives us some nice long term gains
0 · Reply
sam9420
sam9420 Dec. 19 at 6:46 PM
$CING we should be above 6$ now
0 · Reply
Barbaro69
Barbaro69 Dec. 19 at 2:25 PM
$CING i’m in starter 950…make me filthy foogin rich af first SLS
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Dec. 18 at 9:23 PM
$ANRO Easiest call of the year. $SLS And $CING on deck. Congrats to all my longs here.
1 · Reply
GainzWiz
GainzWiz Dec. 18 at 5:46 AM
$CING @SamMusaX hope all is well dude, we miss your weekly patent updates. Hope to get you back soon <3
1 · Reply
TheSuper
TheSuper Dec. 18 at 2:25 AM
$CING any intel or rumors on the patent coming back?
1 · Reply
Jojo_Mojo12
Jojo_Mojo12 Dec. 16 at 6:35 PM
$CING whyd it drop like that?
1 · Reply